A new drug developed by scientists at the University of California, Davis has shown promise in treating the rare and aggressive skin cancer that kills nearly 50,000 people each year.
The drug, called Ezreal, was developed to treat a rare form of eczematous epidermolysis bullosa, or EEB, a cancer that has been linked to the skin-eating disease psoriasis and psorosis.
“Ezreal has a wide spectrum of effects,” said Dr. Jody O’Neill, the lead author of a study published in the journal JAMA Dermatology.
“It does not treat a patient’s normal condition, but rather, it changes how they respond to the immune system.”
Epidermalytic dermatitis is a form of skin disease that has developed in response to the growth of the epidermis, the protective covering of skin cells.
It causes inflammation of the skin cells that produces blisters and sores.
Symptoms of epidermal eczma include redness, blisters, dryness and swelling of the affected area.
It is usually caused by a virus, and most cases go undiagnosed.
“When I first started looking into this drug, it was a completely unknown drug.
And I thought it was really interesting,” said lead author Dr. Tania C. Hwang, a professor of dermatology at UC Davis and a former member of the U.S. National Academy of Sciences.
“When I started studying it, I was surprised by the response.
It was the most exciting drug discovery of the last decade.”
In the new study, published online Feb. 25 in the Journal of Clinical Investigation, the drug targeted a protein in the skin called C1-B6.
The protein was involved in the production of a type of signaling molecule called p17, which plays a role in the immune response and immune response genes.
When the drug was injected into mice, the researchers found that the mice had significantly less C1B6 in their cells than control mice.
The researchers then tested the drug on mice that were genetically engineered to have an altered version of the gene that produces p17.
They found that this gene, known as p16, also was suppressed in the mice treated with the drug.
“This finding suggests that there may be a mechanism that the drug might help regulate C1b6,” said study co-author Dr. Andrew P. Schuetz, a dermatologist at UC Berkeley.
“It could also be a potential target for drug therapy.”
The drug also has the potential to be used in people who already have the disease, but the scientists are working on a way to do so safely.
Dr. O’Neil said she hopes to expand the drug’s use to people with other rare skin cancers, including skin cancers in the mouth, throat and skin, as well as in children.
“The hope is that by getting it into as many people as possible, it will allow people to stop growing skin cancer and potentially stop their skin disease from spreading,” she said.
The team is also looking at the possibility of using the drug to treat patients with eczemic keratosis pilaris, a type that develops in skin that grows in response in response for the immune reaction to the virus that causes the disease.
This type of skin-disease also can affect the immune systems.
“We want to see if this drug can be used to treat this particular disease,” Dr. Schuhetz said.
For more on this research, visit JAMA.